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INTRODUCTION 
 
 
Chronic Obstructive Pulmonary Disease (COPD) is a major cause 
of chronic morbidity and mortality throughout the world. It is a 
preventable and treatable disease with some significant extra pulmonary 
effects that may contribute to severity in individual patients1. It is 
characterized by airflow limitation that is not fully reversible. The airflow 
limitation is usually progressive and associated with an abnormal response 
of the lung to noxious particles or gases. 
 
Nutritional depletion is a prevalent finding in patients who have 
COPD. Several studies have demonstrated that under nutrition is an 
independent predictor of all cause and respiratory morbidity and mortality 
in COPD and has an additive effect with other factors that increase 
mortality. Investigators have identified a positive correlation between 
body weight and the Forced Expiratory Volume in the 1st second2,3. Even 
among stable COPD patients there is a high proportion of under nutrition4. 
COPD patients are at risk of weight loss and nutritional deficiencies 
because of a 15 to 25% increase in resting energy expenditure from 
breathing; a higher energy cost of daily activities; reduced caloric intake 
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relative to need because of dyspnea; and the catabolic effect of 
inflammatory cytokines such as TNF-α5.  
 
At the same time, excessive weight gain must be avoided as 
excessive body weight can lead to a decreased pulmonary reserve. 
 
The exact prevalence of malnutrition in COPD is currently 
unknown because there is no diagnostic method that serves as a reference 
and no widely accepted definition.  
 
Various biochemical parameters that reflect the level of visceral 
protein in the body have also been used in assessing the severity of 
malnutrition.  
 
The present study attempts to determine if there is an association 
between the degree of malnutrition and severity of airflow obstruction. 
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OBJECTIVES OF THE STUDY 
 
1. To determine whether Chronic Obstructive Pulmonary 
Disease is associated with malnutrition. 
 
2. To determine whether there is a relation between the degree 
of malnutrition and severity of airflow obstruction. 
 
3. To determine whether the severity of airflow obstruction 
correlates with biochemical markers of visceral protein 
stores (Serum albumin and Serum prealbumin). 
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REVIEW OF LITERATURE 
 
 Chronic Obstructive Pulmonary Disease  is a major cause of chronic 
morbidity and mortality throughout the world.  Many people suffer from 
this disease for years and die prematurely from it or its complications.  
COPD is the fourth leading cause of death in the world6, and further 
increases in its prevalence and mortality can be predicted in the coming 
decades7. 
 
   Definition:  According to Global initiative for chronic obstructive 
lung disease (GOLD1), COPD is a preventable and treatable disease with 
some significant extra pulmonary effects that may contribute to the 
severity in individual patients.  Its pulmonary component is characterized 
by airflow limitation that is not fully reversible.  The airflow limitation is 
usually progressive and associated with an abnormal inflammatory 
response of the lung to noxious particles or gases1.  The term 
“emphysema” and “chronic bronchitis”, are not included in this  
definition.  Emphysema, or destruction of the gas exchanging surfaces of 
the lung (alveoli), is a pathological term that is often (but incorrectly)  
used clinically and describes only one of several structural abnormalities 
present in patients with COPD1.  Chronic bronchitis, or the presence of                     
cough  and  sputum   production   for  at  least  3  months  in  each  of  two  
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consecutive years, remains a clinically and epidemiologically useful  
term1. 
 
 Worldwide, cigarette smoking is the most commonly encountered 
risk factor for COPD, although in many countries, air pollution resulting 
from the burning of wood and other biomass fuels has also been identified 
as a COPD risk factor1. 
 
 The chronic airflow limitation characteristic of COPD is caused    
by a mixture of small airway disease (obstructive bronchiolitis) and 
parenchymal destruction (emphysema), the relative contributions of  
which vary from person to person1. 
 
Mechanisms Underlying Airflow Limitation in COPD 
 
INFLAMMATION 
 
     Small airway disease   Parenchymal destruction 
 Loss of alveolar attachments              Airway inflammation 
         Airway remodeling      Decrease of elastic recoil 
 
AIRFLOW LIMITATION 
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SPIROMETRIC CLASSIFICATION OF SEVERITY 
Spirometry is essential for diagnosis and provides a useful 
description of the severity of pathological changes in COPD.  Spirometry 
should be performed after the administration of an adequate dose of an 
inhaled bronchodilator (e.g. 400 mcg salbutamol) in order to minimize 
variability8. 
 
 
Spirometric Classification of COPD 
Severity Based on Post-Bronchodilator FEV11 
 
          Stage I : Mild                        FEV1/FVC < 0.70 
                                                        FEV1 >80% predicted 
 
          Stage II : Moderate               FEV1 /FVC < 0.70 
                                                        50% < FEV1 <80% predicted 
 
          Stage III : Severe                   FEV1/FVC < 0.70 
                                                        30% < FEV1 <50% predicted 
 
          Stage IV : Very Severe         FEV1/FVC < 0.70 
                                                        FEV1 <30% predicted or FEV1 50% 
                                                       Predicted plus chronic respiratory  
failure. 
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SYMPTOMS OF COPD 
 The characteristic symptoms of  COPD are chronic  and  
progressive dyspnea, cough and sputum production.  Chronic cough and 
sputum production may precede the development of airflow limitation    
by many years.  Conversely, significant airflow limitation may develop 
without chronic cough and sputum production. 
 
STAGES OF COPD 
 
Stage I: Mild COPD – Characterized by mild airflow limitation 
(FEV1/FVC <0.70; FEV1 >80% predicted).  Symptoms of chronic    cough 
and sputum production may be present, but not always1. 
 
 
Stage II: Moderate COPD – Characterized by worsening airflow 
limitation (FEV1/FVC <0.70; 50% < FEV1 <80% predicted), with 
shortness of breath typically developing on exertion and cough and 
sputum production sometimes also present1. 
 
Stage III:  Severe COPD – Characterized by further worsening of   
airflow limitation (FEV1/FVC <0.70; 30% < FEV1 <50% predicted), 
greater shortness of breath, reduced exercise capacity, fatigue, and 
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repeated exacerbations that almost always have an impact on patients’ 
quality of life1. 
 
Stage IV: Very Severe COPD  - Characterized by severe airflow 
limitation (FEV1/FVC <0.70; FEV1 <30% predicted or FEV1 <50% 
predicted plus the presence of chronic respiratory failure or cor 
pulmonale).  Respiratory failure is defined as arterial partial pressure of 
oxygen (PaO2) less than  8.0 kPa (60 mm Hg) with or without arterial 
partial pressure of CO2 (PaCO2) greater than 6.7 kPa (50 mm Hg) while 
breathing air at sea   level.  Respiratory failure may also lead to effects on 
the heart such as   cor pulmonale (right heart failure).  At this stage, 
quality of life is very appreciably impaired and exacerbations may be life 
threatening1. 
 
EPIDEMIOLOGY 
 
 COPD is underdiagnosed and undertreated, resulting in 
underestimation of the burden of this disease9.  The prevalence of     
COPD is highest in countries where cigarette smoking, for example, is  
still very common10.  Prevalence data based on the presence of airflow 
limitation provide an accurate estimate of the burden of clinically 
significant COPD7. 
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 Two large epidemiologic studies, in which the diagnosis of COPD 
was established using spirometry, evaluated COPD prevalence in 2005.   
In a nationwide Korean survey involving 9,243 subjects, Kim and 
colleagues reported that the prevalence of COPD, determined by criteria 
of the GOLD, was 17.2% among subjects older than 45 years11.  
Prevalence increased with increasing age, especially in males, in those 
with more than 20 pack-years of smoking, and in low-income subjects.  
Most of the COPD found was mild to moderate (FEV1 >50%).     Menezes 
and colleagues reported wide variability in COPD prevalence between five 
major cities in Latin America12. 
 
RISK FACTORS FOR COPD 
 
1) Genes:  polygenic and hereditary deficiency of alpha-I 
antitrypsin13. 
2) Exposure to particles 
• Tobacco smoke14,15. 
• Occupational dusts, organic and inorganic16-19 
• Indoor air pollution  from heating and cooking with  
      biomass in poorly vented dwellings20,21. 
 
• Outdoor air pollution. 
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3) Decreased Lung growth and development22. 
 
4) Oxidative stress. 
 
5) Gender: prevalence is more in males compared to females.  
However in developed countries prevalence is almost equal23,24. 
 
6) Age: prevalence increases with increase in age23. 
 
7) Respiratory infections23. 
 
8) Socioeconomic status: risk of COPD is inversely related to 
socioeconomic status25. 
 
9) Nutrition1-3 
 
10) Co morbidities1 
 
PATHOLOGICAL CHANGES 
 
Proximal airways – Inflammatory cells: Macrophages and CD8+ T 
cells. 
Structural changes: Goblet cells, enlarged submucosal glands and 
squamous metaplasia of epithelium26. 
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Peripheral airways – Inflammatory cells: Macrophages, T lymphocytes 
(CD8+ > CD4+), B lymphocytes and fibroblasts. 
 
Structural changes: Airway wall thickening, peribronchial fibrosis, 
luminal inflammatory exudates and airway narrowing27. 
 
Lung parenchyma – Inflammatory cells: Macrophages, CD8+ T 
lymphocytes. 
 
Structural changes: Alveolar wall destruction, apoptosis of epithelial    
and endothelial cells, Centrilobular and Panacinar emphysema28. 
 
Pulmonary vasculature – Inflammatory cells: Macrophages, T 
lymphocytes. 
 
Structural changes: pulmonary hypertension29. 
 
PATHOGENESIS 
 
 Amplification of the normal inflammatory response of the 
respiratory tract to chronic irritants appears to be seen in COPD. 
 
Inflammatory Cells:  COPD is characterized by recruitment of 
neutrophils,  macrophages and lymphocytes30.  These cells release 
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inflammatory mediators and interact with structural cells in the airways 
and lung parenchyma. 
 
Inflammatory Mediators:  Chemotactic factors like leukotriene B4 and 
interleukin-8, Proinflammatory cytokines like TNF-alpha, IL-1beta, and 
IL-6 and Growth factor TGF-β which are released from the     
inflammatory cells are responsible for inflammation31. 
 
Oxidative Stress: Oxidative stress may be an important amplifying 
mechanism in COPD32.  Oxidants are generated by cigarette smoke and 
other inhaled particulates and released from activated inflammatory     
cells.  Oxidative stress has several adverse consequences in the lungs, 
including activation of inflammatory genes, inactivation of    
antiproteases, stimulation of mucus secretion and stimulation of    
increased plasma exudation. 
 
Protease-Antiprotease Imbalance: There is compelling evidence for     
an imbalance in the lungs of COPD patients between proteases and 
antiproteases1,13. There is increase in proteases such as Neutrophil elastase, 
Cathepsin G, Proteinase 3, Cathepsins B, K, L, S and matrix 
metalloproteinases like MMP-8, MMP-9 and MMP-12.  This is   
associated with decrease in antiproteinases like alpha-1 antitrypsin,     
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alpha-1 antichymotrypsin, Elafin, Cystatins and Tissue inhibitors  of  
MMP 1-4. 
 
PATHOPHYSIOLOGY 
 
1.  Airflow Limitation and Air Trapping: The peripheral airway 
obstruction due to inflammation, fibrosis and luminal exudates leads to 
progressive air trapping during expiration resulting in hyperinflation.  
Hyperinflation increases functional residual capacity which results in 
dyspnea and limitation of exercise capacity. 
 
2.  Gas Exchange Abnormalities: It results in hypoxemia and 
hypercapnia. 
 
3.  Mucus Hypersecretion: It is due to mucosal metaplasia with increased 
numbers of goblet cells in response to chronic airway irritation resulting  
in chronic productive cough. 
 
4.  Pulmonary Hypertension: This may develop late in the course of 
COPD and is due to hypoxic vasoconstriction and structural changes in 
small pulmonary arteries33. 
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PREDICTORS OF MORTALITY IN CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE 
 
 COPD is a major cause of morbidity and mortality in adults         
and is currently the fourth leading cause of death in the world6.  COPD   is 
the only leading cause of death showing increases in prevalence 
worldwide34.  Although COPD is characterized primarily by the presence 
of airflow limitation owing to chronic bronchitis, emphysema, or both, a 
myriad of systemic manifestations that accompany this disease effectively 
can signal an increased risk for mortality.  Recognizing these 
manifestations, provides a more comprehensive assessment of disease 
severity and helps elucidate prognosis. 
 
a)  Forced Expiratory Volume in 1 second (FEV1): 
 
The landmark study of Fletcher and Peto35 published in              
1976, identified a relationship between airflow obstruction and survival             
in a study of over 2700 British men, followed for 20 – 25 years.          
These findings were expanded by Anthonisen and colleagues36 during the 
Intermittent Positive Pressure Breathing Trial (IPPB), which identifies 
both age and FEV1 as independent and   accurate   predictors of mortality. 
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b)  Airway Hyper-responsiveness (AHR): 
 
 The importance of airway hyper-responsiveness (AHR)                   
in obstructive lung diseases is defined better for asthma than for COPD.  
In a mortality assessment of a cohort of 2000 patients followed over         
20 years, Hospers and Colleagues found that increased AHR predicted 
mortality for COPD after adjusting for gender, age, smoking history       
and numerous confounders37.  However, more studies are needed to    
better define this relationship. 
 
c)  Dyspnea 
 
 Dyspnea is the cardinal symptom of COPD38 and the primary reason 
for seeking medical attention39,40.  Numerous studies have identified     
dyspnea as an independent predictor of mortality in COPD.  In a 
prospective, multi-center, 5 year trial, dyspnea was measured by              
the Medical Research Council Dyspnea Scale in a cohort of 227 patients 
who had COPD.  The survival rate was predicted by the degrees               
of dyspnea irrespective of the severity of COPD by FEV141.  
  
d)  Hypoxemia  
  The presence of hypoxemia (PaO2 <55 mmHg or SaO2 <88%) while 
the patient is breathing room air is known to predict mortality.  Neff and 
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Petty first published a 30% to 40% reduction in mortality in COPD 
patients given continuous oxygen42. 
 
e)  Hypercapnia 
 Presence of chronic hypercapnia is associated with negative  
prognostic value for survival in COPD43,44. 
 
f)  Static Hyperinflation 
 In a prospective study, hyperinflation expressed as residual 
volume/total lung capacity proved to be a powerful predictor of 
mortality45. 
 
g)  Pulmonary Hypertension 
 It is defined as a pulmonary artery mean pressure at rest, equal to or 
greater than 20 mmHg at rest.  Increased mortality rate was found in 
patients with severe pulmonary hypertension, irrespective of level of 
airflow obstruction46,47. 
 
h)  Malnutrition 
 Nutritional depletion is a prevalent finding among patients who 
have COPD, in particular those who have advanced disease.  The 
prevalence of weight loss in stable COPD is in the range of 20%, and it 
increases to 35% among those who are hospitalized48,49.  Several studies 
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have found that the body mass index (BMI) is an independent risk factor 
for COPD mortality3,50.  Landbo and colleagues2, in The Copenhagen City 
Heart Study, found BMI to be an independent predictor of all-cause and 
respiratory mortality among COPD patients with FEV1 less than 50% 
predicted.  The impact of weight change on survival in COPD also was 
examined retrospectively by Schols and colleagues51 in 400 COPD 
patients who participated in a pulmonary rehabilitation programme.  A 
low BMI (less than 25 kg/m2) was associated with a significant increase in 
the risk for mortality (P < .001).  In a prospective post hoc analysis of 203 
COPD patients who received nutritional support, weight gain (greater than 
2 Kg/8 wks) was a significant predictor of survival51.  Studies using more 
complex tests to evaluate nutrition, such as midthigh52 and midarm53 
muscle cross-sectional area obtained by CT also have shown significant 
association between malnutrition and mortality in COPD, with a predictive 
value that is superior to that of BMI.  Taken together, the evidence 
suggests that weight loss can be considered an independent risk factor for 
mortality in patients who have COPD.  
 
i)  Exercise capacity: 
 Exercise intolerance affects many patients who have COPD54.  The 
6 minute walk distance test is a simple field test that has been correlated 
with mortality55. 
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j)  Anemia 
 
 Anemia is a common comorbidity in many chronic diseases and its 
importance in COPD is gaining interest.  Recent reports suggests that 
anemia in patients who have COPD may be more prevalent than expected 
and related to mortality56. 
 
 
MULTIDIMENSIONAL MORTALITY RISK ASSESSMENT IN 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
 
 For many years, FEV1 and age were considered the most important 
prognostic indicators of COPD.  Unfortunately, both of them are, for most 
part, irreversible.  Recent evidence shows that multiple factors, other than 
FEV1 can predict mortality in this disease, as discussed earlier.  These 
factors are reflections of the systemic involvement of COPD and many of 
them are amenable to treatment.  In a pioneer study by Celli and 
colleagues57, 207 patients who had COPD were enrolled prospectively and 
the predictive value of numerous variables was evaluated.  The authors 
identified four variables that predicted an elevated risk for death.  BMI 
(B), degree of airflow obstruction (O) as measured by FEV1, dyspnea as 
measured by  the MRC dyspnea scale (D) and excercise capacity as 
measured by 6 metre walk test (E).  These variables were incorporated 
into a multidimensional scale, the BODE index, that ranged from 0 (least 
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risk) to 10 (highest risk).  The authors found that each quartile increase in 
the BODE index score yielded an increase in the risk for mortality. 
 
 
 
Calculation of the BODE Index 
 
BODE score 
Variable 0 1 2 3 
FEV1 % predicted  >65 50 – 65 35 – 49 <35 
Dyspnea: MRC 0 – 1 2 3 4 
6MWD meters >350 250 – 349 150 – 249 <149 
BMI >21 <21 - - 
 
FEV1  - Forced Expiratory volume in the first second 
6MWD – Six Meter Walk Distance 
MRC – Medical Research Council 
BMI – Body Mass Index 
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MALNUTRITION IN COPD 
 
 The effect of nutritional data on respiratory muscle function is 
controversial.  It is postulated that under-nutrition plays an additive role in 
the variation of weakness of respiratory muscles in COPD.   
 
 Studies on re-nutrition in COPD showed an improvement in muscle 
strength suggesting that malnutrition is an important cause of diminished 
muscle strength58.   
 
 A substantial proportion of patients with COPD are found              
to be malnourished.  The incidence depends largely on disease severity. 
Some studies have shown that about 25 percent of patients with COPD 
suffer from under-nutrition59. Those with FEV1 <35%, it is found to be 
50%.  Even patients with a moderate airflow obstruction may have an 
incidence up to 25%60. Poor nutritional status may adversely affect 
respiratory function in COPD patients.   
 
 
 
THE EFFECTS OF MALNUTRTION ON THE RESPIRATORY 
APPARATUS: 
 
 
– Changes in the respiratory musculature. Abnormalities in skeletal 
muscle are common in COPD patients; contractility, strength, and 
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resistance are reduced, while fatigability increases61. The etiology of 
muscular dysfunction in COPD is multifactorial and includes electrolyte 
abnormalities, atrophy due to lack of exercise, prolonged use of drugs 
such as corticosteroids62,63, changes in the geometry of the thoracic cage, 
hypoxia, and malnutrition. Malnutrition decreases muscular strength  and 
resistance, and reduces glycolytic and oxidative capacity in both type I and 
type II fibers. A weak respiratory musculature contributes to dyspnea and 
has a negative impact on exercise tolerance64. 
 
– Morphological changes. In various animal models, the lungs have been 
shown to lose mass as a result of malnutrition, although to a lesser extent 
than the body as a whole. This loss primarily affects protein content but fat 
content also diminishes. From a morphological standpoint this leads to a 
greater tendency of the lung to collapse, elongation of the airspaces, 
destruction of septa, and thinning of the interalveolar walls. These changes 
are due to an increase in proteolytic activity and a decrease in collagen 
content and may be partially reversible if the patient is adequately 
renourished65,66. 
 
– Biochemical changes. Biochemical changes affect the alveolar surfactant 
provoking a decrease in total phospholipids, phosphatidylglycerol, and 
phosphatidylcholine. This triggers a rise in surface tension and a 
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corresponding decrease in the protective effectiveness of the surfactant. 
These changes are due to a reduction in the enzyme activity that regulates 
its synthesis, to a reduced availability of energy substrates, and to 
characteristics of the local oxidative metabolism. These abnormalities may 
be reversible on re-nourishment, and a normal state is recovered more 
rapidly than in the case of connective tissue67.  
In summary (although much remains to be clarified and most of the 
studies in the literature have used animal models), malnutrition appears to 
cause a series of alterations in muscles, especially the diaphragm, and also 
affects the lung parenchyma. The lungs become emphysematous in 
appearance and this changes respiratory dynamics. 
 
EFFECT OF RENUTRITION 
 Nutritional repletion can improve respiratory muscle strength in 
some patients.  When 6 ambulatory patients with COPD were given oral 
nutritional repletion for two weeks, baby weight increased by six percent 
and transdiaphragmatic pressure increased by 41 percent58. 
 
 The mechanisms of improved muscle performance with re-nutrition 
are not clear.  In animal and human studies, chronic hypocaloric dieting 
produced changes in skeletal muscle that may be important in the genesis 
of muscle dysfunction.  These changes include protein catabolism, 
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depletion of glycolytic and oxidative enzymes, reduction in high energy 
phosphate stores, increases in intracellular calcium.  
 
NUTRITIONAL ASSESSMENT IN PATIENTS WITH COPD 
         In general, insufficient attention is paid to the nutritional assessment 
of patients with COPD in routine practice. It should, like spirometry and 
arterial blood gas analysis, be included in the initial clinical evaluation of 
these patients. Regular follow-up of nutritional status is also essential 
because this variable has been shown to have independent prognostic 
value, a more than sufficient reason for its assessment68. Consequently, 
simple, easy-to-use, cheap, and reproducible procedures for the 
assessment of nutritional status are needed. 
 
There is no single ideal nutritional marker, but a combination of 
several simple parameters can facilitate the diagnosis of malnutrition in 
these patients69. Several parameters are used to assess nutritional status 
and they can be basically categorized as either anthropometric or 
biochemical.   
 
– Body weight, which is very easy to measure. A record of weight over 
time is more useful than a single isolated measurement. 
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– Comparison with the predicted weight for height and sex in a specific 
population expressed as ideal body weight, or calculation of BMI. These 
variables are easily calculated. The BMI has been shown to correlate well 
with lung function parameters, such as the diffusing capacity of the lung 
for carbon monoxide, FEV1, and the ratio of FEV1 to forced vital 
capacity. 
 
– Assessment of the muscle compartment using anthropometric data or 
densitometry. 
 
– Evaluation of body composition by measurement of skinfolds or, even 
better, bioelectrical impedance analysis. Body composition, and in 
particular the fat-free mass index, has been shown to be an independent 
predictor of mortality in COPD70. 
 
– Biochemical markers, such as albumin, prealbumin, albumin and 
transferrin. These will very often vary due to non-nutritional factors such 
as liver disease, cardiac failure, long term steroid therapy, etc69. 
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MEASURES  OF VISCERAL PROTEIN STORES 
 
Serum protein levels are important markers of the body protein 
pool. Measurable proteins include albumin, transferrin, transthyretin 
(prealbumin),   retinol-binding   protein  (RBP),  fibronectin, C-reactive   
protein,  interleukins,  and others. Proteins with a long half-life are most 
useful in evaluating chronic nutritional changes in the outpatient setting. 
Proteins with a short half-life are most useful in the acute or subacute 
settings. 
 
Albumin 
Serum albumin levels have long been considered a major measure of 
malnutrition and the defining value for determining the diagnosis of 
kwashiorkor. Albumin levels are highly predictive of mortality in the 
hospital71 and mortality in the general population72. For every 2.5 g/L 
decrease in serum albumin concentration, there is a 24% to 56% increase 
in the likelihood of dying71. 
Albumin has a long half-life of approximately 18 days73.   Serum 
levels of albumin reflect the net result of hepatic synthesis (12–15 g/d), 
plasma distribution, and protein loss.  
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Serum albumin levels often decline rapidly after hospital 
admission74. The rate of fall is too rapid to allow for a nutritional 
explanation. Two reasons appear to explain this fall: postural changes and 
cytokines. Altering posture from the upright to the recumbent position 
produces a decline in serum albumin of 5 g/L. Cytokines such as tumor 
necrosis factor-α, interleukin-2 (IL-2), and IL-6 inhibit albumin 
production by inhibiting albumin gene expression and cause a vascular 
endothelial leak, resulting in an increase plasma clearance rate of 
albumin75. Chronic alteration in serum albumin can occur with diseases 
affecting  hepatic production of albumin (liver disease and congestive 
heart failure) or the rate of albumin loss (nephrotic syndrome and protein-
losing enteropathies). Thus, although serum albumin levels remained the 
gold standard for the diagnosis of protein energy malnutrition, they are a 
somewhat tarnished standard.  
 
Several studies have shown a correlation between low serum 
albumin and the severity of airway obstruction76. Katsura et al found that 
low albumin levels can be a risk factor for poor outcome in the disease77. 
 
Prealbumin 
Prealbumin, also known as transthyretin, is a transport protein for 
thyroxine. Prealbumin is popularized by its short half-life and superior 
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sensitivity in evaluating acute nutritional change78. Because of their long 
half-lives, downward changes of the concentrations of albumin and 
transferrin are not seen until prolonged or severe malnutrition is present78-
80. The long half-lives also prevent the detection of short-term responses to 
nutritional support. Prealbumin levels decrease faster than do levels of 
albumin and transferrin in cases of protein depletion81 and returns to 
normal after nutritional repletion82. Among nursing-home residents who 
were hospitalized, severe hypoprealbuminemia predicted extended 
hospitalization but not mortality83. In cancer patients receiving total 
parenteral nutrition, plasma levels of prealbumin rapidly increased in 
patients who survived and rapidly fell in patients who did not84. Winkler et 
al. showed that, after 1 wk of adequate feeding of malnourished patients, 
only 36% had serum albumin within normal values compared with 
transferrin (80%)and prealbumin (98%)85. If prealbumin fails to increase 
despite 10 to 14 d of adequate parenteral nutrition, it indicates a poor 
prognosis for short-term survival in cancer patients85. Low serum 
prealbumin levels were predictive of death and indicative of sepsis in burn 
patients86. Severely low levels of prealbumin have been shown to increase 
in-hospital stay of nursing-home patients when admitted to the hospital83. 
Prealbumin is a stable and symmetrical tetramer composed of four 
identical subunits87. It is normally bound to the retinol-binding protein 
(RBP) at a 1:1 molar ratio in physiologic pH 6. In addition to thyroxin 
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transport, prealbumin plays a role in vitamin A transportation via this 
complex. Prealbumin has the highest proportion of essential to non-
essential amino acids of any protein in the body. It is rich in tryptophan, 
which plays a major role in the initiation of protein synthesis. Prealbumin 
has a small pool and a half-life of 2 d88. PA levels can be affected by 
factors other than malnutrition. Prealbumin has been noted to be lower in 
women than in men in the same age group89,90. Although aging does not 
affect prealbumin levels in healthy individuals, it seems that a decrease in 
prealbumin levels may occur in very old men (>90 y), so that their values 
fall to within the same range as those in women89. Decreased prealbumin 
levels are seen in end-stage liver disease (presumably due to decrease 
production)91, inflammation92, stress93, and iron deficiency94. Renal 
insufficiency and steroid use each causes an increase in serum prealbumin 
levels95. 
Because of its unique characteristics and its small pool size, 
prealbumin is a better and more sensitive indicator of acute changes in 
protein status in both young and old. 
Studies done on COPD patients have shown that prealbumin levels 
are related to level of airway function. However, all the prealbumin values 
fell within the normal range96. 
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MATERIALS AND METHODS 
 
SETTINGS 
 Out patient clinics at 
• Department of Thoracic Medicine 
   Madras Medical College and Government General Hospital 
            Chennai – 600 003 
• Institute of Thoracic Medicine 
  Chetpet 
  Chennai 
 
ETHICAL COMMITTEE APPROVAL 
 Obtained 
 
STUDY DESIGN 
 Cross sectional study design 
 
PERIOD OF STUDY 
 June 2007 to September 2008 
 
SAMPLE SIZE 
 50 cases 
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CONSENT 
Informed consent was obtained from all patients participating 
in the study 
 
INCLUSION CRITERIA 
1. Patients diagnosed to have Chronic Obstructive Pulmonary    
  Diseases as per GOLD criteria 
2. Patients in the age group 40 – 60 years 
3. Patients on treatment for less than one year 
4. Patients not on corticosteroid 
 
EXCLUSION CRITERIA 
1. Patients with exacerbation of symptoms <2 months prior to 
study 
2. Patients with cor pulmonale 
3. Patients with diabetes mellitus 
4. Critically ill patients 
5. Female patients 
6. Patients with pulmonary tuberculosis 
7. Patients who are unable to perform spirometry 
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8. Patients with bronchial asthma, bronchiectasis, cystic fibrosis, 
upper airway obstruction. 
9. Patients with concomitant diseases that may alter nutritional 
status e.g. heart failure, liver cirrhosis, uncontrolled diabetes 
10. Non smokers 
 
METHODOLOGY 
 Out of 102 patients initially enrolled for the study, 50 patients were 
selected.  Others were excluded as per exclusion criteria. 
 
 The patients were defined as having COPD based on GOLD criteria 
with spirometry showing, post bronchodilator FEV1 / FVC ratio <0.70. 
 
 The analysis was restricted to patients in the age group of 40 – 60 
years.  All the patients chosen were smokers and all the patients were 
males.  This was done to ensure uniformity of analysis (standards for 
variation of prealbumin between various age groups and gender are not 
available). 
 
 For each subject, medical history was obtained and clinical 
examination was done.  All subjects had a baseline blood sugar value and 
renal function tests.  On the study day, height and weight were measured.  
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Weight was measured to the nearest 100 g.  Height was measured to the 
nearest mm using a stadiometer.  Body Mass Index (BMI) was calculated 
using the formula: 
BMI = Weight (kg) / Height (m)2 
 
TRICEPS SKINFOLD THICKNESS (TSF) 
 Triceps skinfold thickness was measured in all subjects in the non 
dominant arm using a standard Vernier calipers97.  Measurement was 
taken mid way between the acromion and olecranon process and was 
measured to the nearest 0.1 mm.  Most population studies show an average 
value of 1.5 + 0.6 cm98. 
 
MIDARM CIRCUMFERENCE (MAC) 
 Midarm circumference of the non-dominant arm was measured 
using a standard measuring tape.  The measurement was done mid way 
between the olecranon process and acromion process and taken to the 
nearest mm99. 
 Nutritional indices were calculated using standard formulae4: 
 
MIDARM MUSCLE CIRCUMFERENCE =  MAC – (3.14 x TSF) 
(MAMC) (cm) 
 
MIDARM MUSCLE AREA             =  (MAMC)2 / 4 x 3.14 
(MAMA) (cm2) 
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MIDARM FAT AREA              = [MAC2/(4x3.14)] - MAMA  
(MAFA) (cm2) 
 
 
FAT / MUSCLE INDEX         =  MAFA / MAMA     
(F/M) 
 
SPIROMETRY 
 
 Spirometry was performed using standard equipment at the 
outpatient departments of Department of Thoracic Medicine, Government 
General Hospital and at Institute of Thoracic Medicine.  FEV1 / FVC ratio 
of <0.70 was used to define airflow obstruction.  Mild, moderate and 
severe airflow obstructions were defined as FEV1 >=80% predicted (stage 
1 of GOLD classification), 50 – 80% predicted (stage 2a) and <50% of 
predicted (stage 2b and 3) respectively1. 
 
LABORATORY INVESTIGATIONS 
 
 Serum prealbumin was done at a private lab using standard 
immunoturbidimetric method100. 
 
 The method gives a reference value of 20 – 40mg%. 
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Serum albumin was measured using spectrophotometric 
method101. 
The reference value was 3.5-5 g/dl. 
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RESULTS 
 
The study population included 50 patients, who were examined and 
evaluated. The following are the findings. 
 
Table 1:Study Population Characteristics 
Parameter Mean S.D 
Age 51.32 yrs 5.85 
Weight 55.1 kg 11.1 
Height 1.60 m 0.07 
Midarm circumference (MAC) 22.9 cm 3.6 
Triceps skinfold (TSF) 1.31 cm 0.43 
Body Mass Index (BMI) 21.40 3.56 
Midarm Muscle Circumference (MAMC) 18.9 cm 2.38 
Midarm Muscle Area (MAMA) 28.9 cm2 7.40 
Midarm Fat Area (MAFA) 14.2 cm2 7.36 
Fat/Muscle Ration (F/M) 0.47 0.11 
Prealbumin 29.41mg% 7.98 
Albumin 3.8g% 0.39 
FEV1 65.6% 15.52 
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Table 2: Age Distribution 
 
Age group Number Percentage 
40 – 44  8 16% 
45 – 49   11 22% 
50 – 54  12 24% 
55 – 60  19 38% 
 
 
 
 
 
 
 
 
 
 
The average age of the study population was 51.32 years. Most of the 
patients (62%) were in the age group between 50 and 60 years. 
 
 
 
 
 
 
16%
22%
24%
38%
40 – 44yr s
45 – 49yrs  
50 – 54yrs 
55 – 60yrs 
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Table 3: COPD SEVERITY (Based on FEV1) 
 
 
Degree of Obstruction FEV1  (% predicted) Number Percentage 
Mild >=80 12 24% 
Moderate 50 – 79  25 50% 
Severe <50 13 26% 
 
 
 
 
 
 
 
 
 
 
 
Of the 50 patients in the study, 12 (24%) had mild airway 
obstruction, 25 (50%) had moderate airway obstruction, and 13 
(26%) had severe airway obstruction 
 
 
 
24%
50%
26%
Mild
Moderate
Severe
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Table 4: Relation between age and severity of obstruction 
 
Age Avg. FEV1 Standard Deviation One way 
ANOVA 
40 – 44  71.50 12.64 
45 – 49   68.45 15.67 
50 – 54  67.25 13.45 
55 – 60  60.42 17.22 
 
P = 0.2922 
Not Significant 
 
  
 
 
 
 
 
 
 
 
 
 
The difference in the degree of airway obstruction among the different age 
groups was not statistically significant. 
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Table 5: Relation between age and serum prealbumin 
 
Age Avg. prealbumin Standard Deviation One way 
ANOVA 
40 – 44  31.95 7.52 
45 – 49   30.01 6.22 
50 – 54  31.01 8.02 
55 – 60  26.98 8.93 
 
P = 0.3848 
Not Significant 
 
 
 
 
 
 
 
 
 
There was no significant difference in prealbumin value among 
different age groups. 
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Table 6: Relation between age and serum albumin 
 
Age Avg. Albumin Standard Deviation One way 
ANOVA 
40 – 44  3.83 0.38 
45 – 49   3.86 0.37 
50 – 54  3.94 0.38 
55 – 60  3.68 0.40 
 
P = 0.3159 
Not Significant 
 
  
 
 
 
 
 
 
 
 
 
There was no  significant difference in serum albumin among 
different age groups. 
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Table 7: Relation between Airway Obstruction and BMI 
 
Airway 
Obstruction 
Mean BMI Standard Deviation One way 
ANOVA 
Mild (n=13) 23.96 1.20 
Moderate (n=25) 22.16 3.28 
Severe (n=12) 17.04 1.27 
P = < .001 
Not Significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 There was a significant difference in BMI value in patients with 
severe  airway obstruction as compared to those with mild and moderate 
obstruction.  However, the difference between the first two groups (mild 
and moderate obstruction) was not statistically significant. 
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Table 8: Relation between Airway Obstruction and 
 Midarm Muscle Area (MAMA) 
 
 
Airway 
Obstruction 
Mean MAMA Standard Deviation One way 
ANOVA 
Mild (n=13) 33.83 4.03 
Moderate (n=25) 29.90 7.50 
Severe (n=12) 21.32 3.23 
P = < 0.001 
Significant 
 
 
 
 
 
 
 
 
 
 
 
There was a significant difference in MAMA value in patients with 
severe  airway obstruction as compared to those with mild and moderate 
obstruction.  However, the difference between the first two groups (mild 
and moderate obstruction) was not statistically significant. 
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Table 9: Relation between Airway Obstruction and Midarm Fat Area 
(MAFA) 
 
 
 
Airway 
Obstruction Mean MAFA Standard Deviation
One way 
ANOVA 
 
Mild (n=13) 18.39 3.67 
 
Moderate (n=25) 15.12 8.56 
 
Severe (n=12) 7.96 1.37 
P = 0.006 
Significant 
 
 
 
 
 
 
 
 
 
 
There was a significant difference in MAFA value in patients with 
severe  airway obstruction as compared to those with mild and moderate 
obstruction.  However, the difference between the first two groups (mild 
and moderate obstruction) was not statistically significant. 
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Table 10: Relation between Airway Obstruction and 
 Serum Prealbumin 
 
 
Airway 
Obstruction 
Mean Serum 
Prealbumin Standard Deviation
One way 
ANOVA 
 
Mild (n=13) 38.35 3.19 
 
Moderate (n=25) 29.86 4.71 
 
Severe (n=12) 18.78 2.45 
P < 0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
There was a statistically significant difference between the Serum 
Prealbumin level and degree of airway obstruction among all three groups.  
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Table 11: Relation between Airway Obstruction and Serum Albumin 
 
 
Airway 
Obstruction 
Mean Serum 
Albumin Standard Deviation
One way 
ANOVA 
 
Mild (n=13) 4.28 0.15 
 
Moderate (n=25) 3.78 0.23 
 
Severe (n=12) 3.34 0.17 
 
P = 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
There was a statistically significant difference between the Serum 
Albumin level and degree of airway obstruction among all three groups 
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Table 12: Correlation of Severity of Airway Obstruction 
 with other parameters 
 
 
Parameter BMI MAMA MAFA F/M Pre Alb. Alb. 
 
r Value 0.75 0.69 0.55 0.58 0.76 0.68 
 
P value 0.001 0.001 0.001 0.001 0.001 0.001 
 
0-0.2    poor correlation    0.2-0.4 fair 
0.4-0.6  moderate                                            0.6-0.8         substantial 
0.8-1.0  good  
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Table 13: Quartile distribution of Body Mass Index according to  
severity of airway obstruction 
 
Severity of airway obstruction BMI 
Mild  Moderate Severe 
Significance 
<P25 (n=13) 0 (0%) 3 (6%) 10 (20%)
P 26-75 (n=24) 4 (8%) 18 (36%) 2 (4%) 
> P 75 (n=13) 9 (18%) 4 (8%) 0 (0%) 
 
  p < 0.01 
 
                                                                                 P- Percentile 
 
 
Of the 12 (24%) patients with severe airway obstruction, 10 patients 
were found to be in the lower quartile of body mass index of the study 
population. 
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Table 14: Severity of airway obstruction in the under nourished 
 
 
Severity of airway obstruction 
Mild  Moderate  Severe 
Significance 
BMI <18.5 kg/m2 (n=14)
 0 3 11   p < 0.01 
 
 
Out of the 50 patients, 14 (28%) were found to have a BMI<18.5 
(under nourished status). Of these, 3 had moderate airway obstruction and 
11 had severe airway obstruction. 
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Table 15: Quartile distribution of Midarm Muscle Area according  
to severity of airway obstruction 
 
Severity of airway obstructionMAMA 
Mild  Moderate Severe 
Significance 
 
<P25 
(<23.7)  
(n=13) 
0 (0%) 4 (8%) 9 (18%)
 
P 26-75 
(23.7-32.9) 
(n=24) 
6 (12%) 15 (30%) 3 (6%) 
 
> P 75 
(>32.9) 
(n=13) 
7 (14%) 6 (12%) 0 (0%) 
 
  
  
 
 
p < 0.01 
 
 
                                                                       P – percentile  
 
 
 
Of the 12 (24%) patients with severe airway obstruction, 9 
patients were found to be in the lower quartile of Midarm Muscle 
Area of the study population. 
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Table 16: Quartile distribution of Midarm Fat Area according to 
severity of airway obstruction 
 
Severity of airway obstruction MAFA 
Mild  Moderate Severe 
Significance 
 
<P25 
(<9.8) 
0 (0%) 2 (4%) 11 (22%)
 
P 26-75 
(9.8-17.1) 
5 (10%) 18 (36%) 1 (2%) 
 
> P 75 
(>17.1) 
8 (16%) 5 (10%) 0 (0%) 
 
 
 
 
p < 0.5 
 
 
                                                                       P – Percentile 
 
 
 
 
Of the 12 (24%) patients with severe airway obstruction, 11 patients 
were found to be in the lower quartile of Midarm Fat Area in the study 
population. 
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Table 17: Severity of airway obstruction in patients with 
Hypoalbuminemia 
 
 
 
Severity of airway obstruction
Mild  Moderate  Severe 
Significance 
Sr. Albumin<3.5g% 
 0 1 8   p < 0.01 
 
 
 
 
9 (18%) patients in the study were found to have a Serum albumin 
level of less than 3.5g%. Of these, 1 patient had moderate airway 
obstruction and 8 had severe airway obstruction. 
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DISCUSSION 
 
Several relevant observations were made in the present study. 
Comparisons of the present study with previous studies is difficult because 
the criteria for malnutrition are not universally accepted. 
 
1. AGE:  
   The average age of the study population in the present study 
was 51.32 years (Table 1). In a similar study done by Soler et al4, the 
average age was 69 years. The patients in the present study were in the 
age group of 40 to 60 years (Table 2). This was chosen because the 
FEV1 has been found to progressively decrease as the age advances. 
The selection of the patients within a narrower age group was done to 
ensure uniformity in the study group.  
 
  In the study, there was no statistically significant difference 
in the various nutritional parameters and biochemical parameters 
among the different age groups.    
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2. SEX: 
All the patients selected for the study were male. This was 
done because the biochemical parameter prealbumin has been found to 
vary between males and females. Females have been found to have a 
lower value of prealbumin. The study by Soler et al4 included 177 male 
patients and 1 female patient. 
 
3. FORCED EXPIRATORY VOLUME IN THE FIRST SECOND: 
                 The average FEV1 of the population in the present study 
was 65.6 (percent predicted) compared with 44.6 (percent predicted) in 
the study by Soler et al4. The population was divided into mild, 
moderate and severe airway obstruction based on GOLD criteria1. 
 
    In the present study, 12 (24%)  patients  were found to have 
severe obstruction with FEV130-50%, 25  (50%) patients had moderate 
airway obstruction with FEV1 between 50-80%, and 13 (26%) had mild 
airway obstruction with FEV1. Patients with FEV1 of <30% were not 
selected as these patients had frequent exacerbations of symptoms ( 
Table 3).  
FEV1   did not vary significantly among the different age groups.  
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4. ANTHROPOMETRIC MEASURES: 
The following anthropometric measures were analysed in the 
study population: 
 
a)  WEIGHT AND HEIGHT:  
  The average weight of the population in the present study was 
55.1 kg ( Table 1) compared with 74.1 kg in the study by Soler et al4. 
The average height of the population in the present study was 1.60m 
(Table 1) compared with 1.62m in the study by Soler et al.4  The 
difference can probably be explained by the fact that the present study 
was done on an Indian population which has a lower average body 
weight than Western population. 
 
b) BODY MASS INDEX: 
  The average BMI of the population in the present study was 
21.4 kg/m2 (Table 1) compared with 28.2 kg/m2 in the study by Soler et 
al4. There are no standards available for the BMI in the Indian 
population.  
  
       In the present study, a correlation was found between a lower BMI 
and the severity of airway obstruction. BMI of less than 18.5, which is 
considered as under-nutrition in general population102 was found in 14 
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(28%) patients. Of these 3 were having moderate airway obstruction 
and 11 were having severe airway obstruction (Table 14). There was no 
statistically significant difference in the BMI between groups with mild 
and moderate airway obstruction. There was a significant difference in 
the mean BMI between the population with severe airway obstruction 
and the above two groups (Table 7). The present study found a 
substantial correlation between low BMI and severity of airway 
obstruction of 0.75 (Table 12). 
  
In the study by Soler et al4, BMI less than 20 kg/m2 was taken as 
undernourished. 3 of those patients were found to have moderate 
airway obstruction and 4 were found to have severe airway obstruction. 
 
c) MID ARM CIRCUMFERENCE: 
   The average midarm circumference in the present 
study was 22.9 cm (Table 1). Anthropometric studies have shown that 
a midarm circumference of less than 23 cm signifies under-nutrition99.  
 
d) TRICEPS SKINFOLD THICKNESS: 
   The average triceps skinfold thickness in the present 
study population was 1.31 cm (Table 1). Although there are no 
standards, population studies have found a value of 0.9 – 2.1 cm98.  
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e) MIDARM MUSCLE AREA (MAMA): 
   This value was used to assess the muscle mass of the 
patient. The mean MAMA in the present study was found to be 28.9 
cm2  (Table 1).Of these 13 (26%) of the patients were found to be in the 
lower quartile (< 25th percentile) of the distribution. Of these, 9 patients 
had severe airway obstruction and 4 patients had moderate airway 
obstruction. This set of patients were considered as having severe 
muscle mass depletion (Table 15).  
 
In the study by Soler et al4, out of 177 patients, 84 (47%) of the 
patients were found to have muscle mass depletion. Of these, 43 
patients had severe airway obstruction.  
 
The present study showed a statistically significant difference in 
MAMA between the population group with severe airway obstruction 
and those with mild and moderate airway obstruction (Table 8). 
 
The present study also showed a correlation between decrease in 
muscle mass and severity of airway obstruction (with a correlation 
coefficient of 0.69) (Table 12). 
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f) MIDARM FAT AREA (MAFA): 
   This measure was used to assess the fat store of the 
body. The mean MAFA in the present study was found to be 14.2 cm2 
(Table 1). Of these 13 (26%) of the patients were found to be in the 
lower quartile (< 25th percentile) of the distribution. Of these, 11 
patients had severe airway obstruction and 2 patients had moderate 
airway obstruction. This set of patients were considered as having 
severe fat store depletion (Table 16).  
 
In the study by Soler et al4, out of 177 patients, 34 (19%) of the 
patients were found to have muscle mass depletion. Of these, 20 
patients had severe airway obstruction.  
 
The present study showed a statistically significant difference in 
MAFA between the population group with severe airway obstruction 
and those with mild and moderate airway obstruction. There was no 
significant difference between the latter two groups ( Table 9). 
 
The present study also showed a  correlation between decrease in 
muscle mass and severity of airway obstruction (with a correlation 
coefficient of 0.55) (Table 12). 
 
 58
The degree of muscle mass depletion was found to correlate more 
strongly with the degree of airway obstruction than the degree of fat 
depletion. This corresponded with the findings in the study by Soler et 
al4. 
 
5. MEASURES OF VISCERAL PROTEIN STORES: 
Serum prealbumin and serum albumin were used as the 
measures of visceral protein in the present study. 
 
a. SERUM PREALBUMIN:   
The average prealbumin value in the study population was 29.41 
mg/dl (Table 1). The present study showed an inverse correlation 
between the level of prealbumin and the severity of airway 
obstruction (with a correlation coefficient of 0.76) (Table 12). There 
was a statistically significant difference in the average values 
between the three groups of airway obstruction (mild, moderate and 
severe) (Table 10). 
 
In the study by Braun et al96, the prealbumin level was correlated 
with Arterial oxygen saturation. A statistically significant 
correlation value of 0.42 was found in the study. 
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Studies done previously have demonstrated that prealbumin is 
not an accurate marker for malnutrition in various disease states, as 
it is influenced by other factors.  
The present study however, demonstrated that there is a 
significant correlation between severity of airway obstruction and 
decrease in serum prealbumin.  
 
b) SERUM ALBUMIN:  
       The average serum albumin in the study population was 3.8 
g/dl (Table 1). The present study showed a statistically significant 
inverse correlation between the degree of airway obstruction and 
level of serum albumin (with a correlation coefficient of 0.68) 
(Table 12). There was a statistically significant difference in the 
average albumin values between the three groups (mild, moderate 
and severe airway obstruction) (Table 11). 
 
9 (18%) of the 50 patients were found to have a serum 
albumin value of less than 3.5g/dl. Of these, 8 patients had severe 
airway obstruction and 1 patient had moderate airway obstruction ( 
Table 17). 
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In the study done by Soler et al4, of the 177 patients, 17 
(9.6%) patients were found to have a serum albumin value of less 
than 3.5g/dl.  This value was not statistically significant.  
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STUDY LIMITATIONS 
 
1. The study is a hospital based study and may not be 
representative of the general population. 
2. As the study is designed as a cross sectional study, the present 
analysis will be unable to elucidate the prognostic indications of 
the nutritional indices. 
3. The patients were on different durations of treatment and 
different drugs. These may have an effect on the findings of the 
study. 
4. Spirometry is a user dependent method of assessment and may 
not always accurately assess the degree of airway obstruction. 
5. The study population involved a set of patients within a narrow 
age group. The findings may not be extrapolated to other age 
groups 
6. The study population did not include females. 
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CONCLUSIONS 
 
1. A significant number of outpatients with Chronic Obstructive 
Pulmonary Disease were found to be undernourished. 
2. The anthropometric measures of nutrition (Body Mass Index, Body 
muscle mass, Body fat stores) were related inversely with the 
degree of airway obstruction. 
3. Measures of visceral protein stores (Serum prealbumin and Serum 
albumin) correlated inversely with severity of airway obstruction. 
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LIST OF ABBREVIATIONS 
 
 
COPD                              Chronic Obstructive Pulmonary Disease  
GOLD                              Global Initiative for Chronic Obstructive                      
                                          Pulmonary Disease 
FEV1                                 Forced Expiratory Volume in the first second  
FVC                                  Forced Vital Capacity 
BMI                                  Body Mass Index 
MAC                                 Midarm Circumference 
TSF                                   Triceps skinfold thickness 
MAMC                             Midarm Muscle Circumference 
MAMA                             Midarm Muscle Area 
MAFA                              Midarm Fat Area 
F/M                                   Fat / Muscle index 
TNF                                  Tumour Necrosis Factor 
IL                                      Interleukin 
TGF                                  Transforming Growth Factor 
AHR                                 Airway Hyper responsiveness 
PaO2                                                   Arterial partial pressure of oxygen 
PaCO2                              Arterial partial pressure of carbon dioxide 
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PROFORMA FOR ASSESSMENT OF NUTRITIONAL 
STATUS IN COPD PATIENTS 
 
 
 
 
Name: 
 
Age:   
 
Sex:                                   
 
Address: 
 
 
Occupation: 
 
OP No. 
 
Smoker Y/N: 
 
Symptoms:           h/o cough 
                                  h/o sputum production 
                                  h/o breathlessness 
 
Co-morbidities:         h/o Diabetes Mellitus 
                                  h/o Hypertension 
                                  h/o Coronary artery disease/ congestive heart failure 
                                  h/o liver disease 
                                  h/o Tuberculosis 
 
Treatment History:    Bronchodilators 
                                  Inhaled/systemic steroids 
                                  Anti tuberculous drugs 
 
Family History:         Diabetes Mellitus 
                                  Hypertension 
                                  Tuberculosis 
                                  Malignancy 
                                  Coronary Artery Disease 
 
EXAMINATION: 
 81
 
Height (m): 
Weight (kg): 
Blood Pressure: 
Pulse: 
Midarm Circumference (cm): 
Triceps Skinfold Thickness (cm): 
 
 
Cardiovascular System: 
 
 
 
Respiratory System: 
 
 
 
Abdomen: 
 
 
 
Central Nervous System: 
 
 
 
 
INVESTIGATIONS: 
 
Blood Glucose: 
Blood Urea: 
Serum Creatinine: 
Serum Electrolytes: 
 
Blood Counts:        Hemoglobin:                                           Total Count: 
                               Differential Count:                                   ESR:                    
 
Liver Function Tests: 
 
 
MEASURES OF VISCERAL PROTEIN STORES: 
 
Serum Albumin: 
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Serum Prealbumin: 
 
 
 
ANTHROPOMETRIC MEASURES: 
 
Body Mass Index: 
 
Midarm Muscle Circumference: 
 
Midarm Muscle Area: 
 
Midarm Fat Area: 
 
Fat/Muscle Ratio: 
 
 
 
SPIROMETRY: 
 
FEV1  (Percent predicted): 
 
      
FEV1 /FVC (Percentage): 
 
 
Severity of airway obstruction: Mild / Moderate / Severe 
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PATIENT CONSENT FORM 
 
STUDY TITLE: 
"EVALUATION OF NUTRITIONAL STATUS IN PATIENTS WITH CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE" 
 
Study centre            :          Institute of Internal Medicine and Department of  Thoracic 
Medicine                                                                                                  
                                           Madras Medical College 
Patient’s Name        :        ________________________________________________ 
Patient’s Age           :        ________________________________________________ 
Identification No.    :        ________________________________________________ 
 
                                                                                          Patient’s may (√ ) these boxes 
 
I confirm that I have understood the purpose of procedure of the above study. I have had the 
opportunity to ask questions and all my questions and doubts have been answered to complete 
satisfaction.       
          
I understand that my participation in the study is voluntary and that I am free to withdraw at 
any time without giving any reason, without my legal rights being affected.  
 
I understand that the sponsor of this clinical study, others working on the sponsor’s behalf, the 
ethics committee and the regulatory authorities will not need my permission to look at my 
heath records both in respect to the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study. I agree to this access. However, I 
understand that my identity will not be revealed in any information released to third parties, or 
published, unless as required under the law. I agree not to restrict the use of any data or 
results that arise from this study.      
 
I agree to take part in the above study and to comply with instructions given during the study 
and to co-operate with the study team, and to immediately inform the study staff if I suffer 
from any deterioration of health or any unexpected or unusual symptoms.  
 
I hereby consent to participate in this study on “Evaluation of Nutritional status in patients 
with chronic obstructive pulmonary disease”. I hereby give permission to undergo complete 
clinical examination, and diagnostic tests.    
 
 
Signature/Thumb impression ________________  Place___________ Date________ 
  of the patient 
 
Patient’s Name and Address _____________________________________________ 
 
                                                ____________________________________________  
 
Signature of the Investigator _________________ Place_________  Date_________ 
 
Study Investigator’s Name  _______________________________ 
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